Geron (GERN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Geron

NasdaqGS•Healthcare•Biotechnology

$1.40-0.11(-0.07%)After hours

Market Cap

$885,318.755

P/S

0.0x

P/B

0.0x

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

How this company scores

AverageMetricSide Score: 56/100

Strongest: Growth (23/25); weakest: Cash & Earnings Quality (10/25).

Profitability10/25

Growth23/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality10/25

Strengths

Growing revenueCash-backed earningsProfit converts from growthConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.0x5y range 0.0x – 5442.7x

Currently below its 20-quarter median.

P/B · 0.0x5y range 0.0x – 11.6x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $885,318.755

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $243.79M
Q. Revenue: $57.48M
TTM EBITDA: $-51.02M
TTM Op. Income: $-51.77M
Q. Op. Income: $-12.50M
TTM Net Income: $-67.61M
Q. Net Income: $-16.68M
EPS: $-0.02
Shares Out.: $670,696

$243.79M in TTM revenue grew 37.8% YoY, reaching $57.48M last quarter. TTM EBITDA of $-51.02M and TTM operating income of $-51.77M show growth is flowing through to the bottom line. However, net income is negative at $67.61M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 83.9%
EBITDA Margin: -21.5%
Op. Margin: -21.7%
Net Margin: -29.0%

Op. margin of -21.7% is up 3.7% YoY — cost efficiency is improving. Net margin at -29.0% and gross margin of 83.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 14% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.0x
P/B Ratio: 0.0x

P/S of 0.0x and P/B of 0.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $519.01M
Cash: $62.64M
Long-Term Debt: $120.13M
Book Value: $218.61M
D/E Ratio: 0.5
Debt/EBITDA: N/A

With $519.01M in assets and $120.13M in long-term debt, D/E is 0.5and book value is $218.61M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is up 20% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-15.83M
TTM Free Cash Flow: $-114.38M
FCF Margin: -46.9%
FCF / Net Income: 1.7

TTM FCF of $-114.38M on $-15.83M in operating cash flow. The FCF / Net Income ratio of 1.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 36% — an improving trend.